Neoadjuvant and Adjuvant Chemotherapy in Resected Pulmonary Large Cell Neuroendocrine Carcinomas: A Single Institution Experience
Inderpal S. Sarkaria(Memorial Sloan Kettering Cancer Center), Valerie W. Rusch(Memorial Sloan Kettering Cancer Center), Gabriel Sica(Emory University), Bernard J. Park(Memorial Sloan Kettering Cancer Center), Akira Iyoda(Toho University), Camelia S. Sima(Memorial Sloan Kettering Cancer Center), Deborah Kuk(Memorial Sloan Kettering Cancer Center), M. Catherine Pietanza(Merck & Co., Inc., Rahway, NJ, USA (United States)), William D. Travis(Memorial Sloan Kettering Cancer Center), Mee Soo Roh(Memorial Sloan Kettering Cancer Center)
Cited by 110
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k